Symbols / TLSA
TLSA Chart
About
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 178.15M |
| Enterprise Value | 159.21M | Income | -12.84M | Sales | — |
| Book/sh | 0.08 | Cash/sh | 0.06 | Dividend Yield | — |
| Payout | 0.00% | Employees | 9 | IPO | — |
| P/E | — | Forward P/E | -7.01 | PEG | — |
| P/S | — | P/B | 18.18 | P/C | — |
| EV/EBITDA | -8.62 | EV/Sales | — | Quick Ratio | 1.65 |
| Current Ratio | 1.72 | Debt/Eq | 1.16 | LT Debt/Eq | — |
| EPS (ttm) | -0.12 | EPS next Y | -0.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2022-12-27 19:00 | ROA | -83.78% |
| ROE | -232.31% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 127.25M |
| Shs Float | 67.25M | Short Float | 1.77% | Short Ratio | 4.72 |
| Short Interest | — | 52W High | 2.60 | 52W Low | 0.73 |
| Beta | 0.25 | Avg Volume | 312.22K | Volume | 223.93K |
| Target Price | $8.04 | Recom | None | Prev Close | $1.34 |
| Price | $1.40 | Change | 4.48% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.04
Mean price target
2. Current target
$1.40
Latest analyst target
3. DCF / Fair value
$-0.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.40
Low
$8.04
High
$8.04
Mean
$8.04
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2022-06-13 | init | ThinkEquity | — → Buy | $4 |
- New nasal treatment calms brain immune activity in progressive MS patients - Stock Titan Wed, 25 Feb 2026 12
- Tiziana Life Sciences Ltd's (NASDAQ:TLSA) largest shareholders are retail investors with 53% ownership, insiders own 43% - Yahoo Finance Mon, 01 Sep 2025 07
- Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab - Quiver Quantitative Mon, 15 Dec 2025 08
- After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued? - Morningstar Wed, 29 Oct 2025 07
- How to buy Tesla stock (TSLA) - NerdWallet Fri, 09 Jan 2026 08
- Tiziana Life Sciences withdraws proposed share offering - Proactive financial news Mon, 15 Dec 2025 08
- Tiziana Life Sciences (Nasdaq: TLSA) to spin out IL-6 asset into new listed company - Stock Titan ue, 02 Dec 2025 08
- Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot (NASDAQ:TLSA) - Seeking Alpha Fri, 31 Oct 2025 07
- How to Turn the Volatility in Tesla Stock into a 20% Upside Opportunity with Just 0.3% Downside Risk - Barchart.com Fri, 19 Dec 2025 08
- While insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownership - Yahoo Finance Mon, 09 Feb 2026 08
- Tiziana leaders invest in $8.8M raise to finish Phase 2 na-SPMS, MSA trials - Stock Titan Fri, 16 Jan 2026 08
- Tesla Ahead of Shareholder Meeting: Buy, Sell or Hold TSLA Stock? - Yahoo Finance Wed, 05 Nov 2025 08
- Biotech behind nasal antibody for Alzheimer's to ring Nasdaq bell - Stock Titan Wed, 17 Dec 2025 08
- Tiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord Injury - Yahoo Finance ue, 23 Sep 2025 07
- Tiziana (NASDAQ: TLSA) to present foralumab update at Jefferies London Conference Nov. 19 - Stock Titan hu, 13 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -513.20K | -84.42K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.29 | 0.21 | 0.00 | 0.12 |
| NormalizedEBITDA | -14.86M | -16.73M | -14.44M | -26.34M |
| TotalUnusualItems | -1.76M | -402.00K | -869.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -1.76M | -402.00K | -869.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.86M | -17.69M | -15.40M | -23.42M |
| ReconciledDepreciation | 124.00K | 96.00K | 51.00K | 141.00K |
| ReconciledCostOfRevenue | 0.00 | |||
| EBITDA | -16.62M | -17.14M | -15.31M | -26.34M |
| EBIT | -16.74M | -17.23M | -15.36M | -26.48M |
| NetInterestIncome | 808.00K | 1.14M | -6.00K | -176.00K |
| InterestExpense | 6.00K | 10.00K | 38.00K | 176.00K |
| InterestIncome | 814.00K | 1.15M | 32.00K | 0.00 |
| NormalizedIncome | -10.62M | -17.37M | -14.53M | -23.42M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.86M | -17.69M | -15.40M | -23.42M |
| TotalExpenses | 15.79M | 17.98M | 14.59M | 27.37M |
| TotalOperatingIncomeAsReported | -15.79M | -17.98M | -14.59M | -27.37M |
| DilutedAverageShares | 106.67M | 102.47M | 101.53M | 97.93M |
| BasicAverageShares | 106.67M | 102.47M | 101.53M | 97.93M |
| DilutedEPS | -0.11 | -0.17 | -0.15 | -0.24 |
| BasicEPS | -0.11 | -0.17 | -0.15 | -0.24 |
| DilutedNIAvailtoComStockholders | -11.86M | -17.69M | -15.40M | -23.42M |
| NetIncomeCommonStockholders | -11.86M | -17.69M | -15.40M | -23.42M |
| NetIncome | -11.86M | -17.69M | -15.40M | -23.42M |
| NetIncomeIncludingNoncontrollingInterests | -11.86M | -17.69M | -15.40M | -23.42M |
| NetIncomeContinuousOperations | -11.86M | -17.69M | -15.40M | -23.42M |
| TaxProvision | -4.88M | 449.00K | 0.00 | -3.24M |
| PretaxIncome | -16.75M | -17.24M | -15.40M | -26.66M |
| OtherIncomeExpense | -1.76M | -402.00K | -804.00K | 893.00K |
| OtherNonOperatingIncomeExpenses | 65.00K | 893.00K | ||
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| GainOnSaleOfPPE | 0.00 | 0.00 | ||
| WriteOff | 0.00 | 0.00 | ||
| GainOnSaleOfSecurity | -1.76M | -402.00K | -869.00K | |
| NetNonOperatingInterestIncomeExpense | 808.00K | 1.14M | -6.00K | -176.00K |
| InterestExpenseNonOperating | 6.00K | 10.00K | 38.00K | 176.00K |
| InterestIncomeNonOperating | 814.00K | 1.15M | 32.00K | 0.00 |
| OperatingIncome | -15.79M | -17.98M | -14.59M | -27.37M |
| OperatingExpense | 15.79M | 17.98M | 14.59M | 27.37M |
| OtherOperatingExpenses | 10.56M | 9.87M | 1.63M | 13.31M |
| ResearchAndDevelopment | 5.23M | 8.11M | 12.96M | 13.21M |
| SellingGeneralAndAdministration | 0.00 | 0.00 | 855.00K | |
| GeneralAndAdministrativeExpense | 855.00K | |||
| SalariesAndWages | 0.00 | 0.00 | 855.00K | |
| GrossProfit | 0.00 | |||
| CostOfRevenue | 0.00 | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 1.57M | 1.68M | |
| OrdinarySharesNumber | 111.46M | 101.51M | 100.59M | 102.27M |
| ShareIssued | 111.46M | 103.09M | 102.27M | 102.27M |
| TotalDebt | 106.00K | 247.00K | 365.00K | 0.00 |
| TangibleBookValue | 3.94M | 5.54M | 19.57M | 41.15M |
| InvestedCapital | 3.94M | 5.54M | 19.57M | 41.28M |
| WorkingCapital | 160.00K | 798.00K | 17.62M | 41.13M |
| NetTangibleAssets | 3.94M | 5.54M | 19.57M | 41.15M |
| CapitalLeaseObligations | 106.00K | 247.00K | 365.00K | 0.00 |
| CommonStockEquity | 3.94M | 5.54M | 19.57M | 41.28M |
| TotalCapitalization | 3.94M | 5.54M | 19.57M | 41.28M |
| TotalEquityGrossMinorityInterest | 3.94M | 5.54M | 19.57M | 41.28M |
| StockholdersEquity | 3.94M | 5.54M | 19.57M | 41.28M |
| OtherEquityInterest | 8.56M | 7.13M | 5.89M | 14.49M |
| GainsLossesNotAffectingRetainedEarnings | 116.99M | 117.06M | 115.57M | 119.15M |
| OtherEquityAdjustments | 118.70M | 118.70M | 118.70M | 118.70M |
| ForeignCurrencyTranslationAdjustments | -1.71M | -1.64M | -3.13M | 454.00K |
| TreasuryStock | 0.00 | 1.57M | 1.32M | 0.00 |
| RetainedEarnings | -144.83M | -133.68M | -116.26M | -108.06M |
| AdditionalPaidInCapital | 23.11M | 16.49M | 15.60M | 15.60M |
| CapitalStock | 111.00K | 103.00K | 102.00K | 102.00K |
| CommonStock | 111.00K | 103.00K | 102.00K | 102.00K |
| TotalLiabilitiesNetMinorityInterest | 7.35M | 6.65M | 6.91M | 7.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 109.00K | 243.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 109.00K | 243.00K | 0.00 |
| LongTermCapitalLeaseObligation | 0.00 | 109.00K | 243.00K | 0.00 |
| CurrentLiabilities | 7.35M | 6.54M | 6.66M | 7.55M |
| OtherCurrentLiabilities | 12.00K | 14.00K | 9.00K | 10.00K |
| CurrentDebtAndCapitalLeaseObligation | 106.00K | 138.00K | 122.00K | |
| CurrentCapitalLeaseObligation | 106.00K | 138.00K | 122.00K | 0.00 |
| PayablesAndAccruedExpenses | 7.23M | 6.39M | 6.53M | 7.54M |
| CurrentAccruedExpenses | 1.65M | 2.25M | 1.57M | 1.77M |
| Payables | 5.58M | 4.14M | 4.96M | 5.76M |
| DuetoRelatedPartiesCurrent | 0.00 | 1.35M | ||
| AccountsPayable | 5.58M | 4.14M | 4.96M | 4.41M |
| TotalAssets | 11.28M | 12.18M | 26.48M | 48.83M |
| TotalNonCurrentAssets | 3.78M | 4.85M | 2.19M | 147.00K |
| NonCurrentAccountsReceivable | 130.00K | |||
| InvestmentsAndAdvances | 3.59M | 4.55M | 1.81M | 0.00 |
| LongTermEquityInvestment | 3.59M | 4.55M | 1.81M | 0.00 |
| GoodwillAndOtherIntangibleAssets | 0.00 | 0.00 | 130.00K | |
| NetPPE | 187.00K | 293.00K | 389.00K | 17.00K |
| AccumulatedDepreciation | -60.00K | |||
| GrossPPE | 187.00K | 293.00K | 389.00K | 17.00K |
| OtherProperties | 187.00K | 293.00K | 389.00K | 17.00K |
| MachineryFurnitureEquipment | 77.00K | |||
| CurrentAssets | 7.51M | 7.34M | 24.28M | 48.68M |
| HedgingAssetsCurrent | 0.00 | |||
| PrepaidAssets | 92.00K | 102.00K | 170.00K | 1.22M |
| Receivables | 3.69M | 6.05M | 5.99M | 5.27M |
| OtherReceivables | 53.00K | 121.00K | 130.00K | 80.00K |
| DuefromRelatedPartiesCurrent | 3.61M | 2.14M | 1.61M | 456.00K |
| TaxesReceivable | 32.00K | 3.79M | 4.25M | 4.74M |
| CashCashEquivalentsAndShortTermInvestments | 3.72M | 1.18M | 18.12M | 42.19M |
| CashAndCashEquivalents | 3.72M | 1.18M | 18.12M | 42.19M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -1.54M | -15.70M | -19.61M | -21.78M |
| RepaymentOfDebt | -141.00K | -119.00K | -55.00K | -152.00K |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 4.57M | 24.00K | 0.00 | 0.00 |
| CapitalExpenditure | -19.00K | -22.00K | ||
| EndCashPosition | 3.72M | 1.18M | 18.12M | 42.19M |
| BeginningCashPosition | 1.18M | 18.12M | 42.19M | 65.82M |
| EffectOfExchangeRateChanges | -367.00K | -28.00K | -398.00K | -1.98M |
| ChangesInCash | 2.91M | -16.91M | -23.67M | -21.66M |
| FinancingCashFlow | 4.50M | 40.00K | -55.00K | -23.00K |
| CashFlowFromContinuingFinancingActivities | 4.50M | 40.00K | -55.00K | -23.00K |
| ProceedsFromStockOptionExercised | 75.00K | 135.00K | 0.00 | 129.00K |
| NetCommonStockIssuance | 4.57M | 24.00K | 0.00 | 0.00 |
| CommonStockIssuance | 4.57M | 24.00K | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -141.00K | -119.00K | -55.00K | -152.00K |
| NetShortTermDebtIssuance | 0.00 | 0.00 | ||
| ShortTermDebtIssuance | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | -141.00K | -119.00K | -55.00K | -152.00K |
| LongTermDebtPayments | -141.00K | -119.00K | -55.00K | -152.00K |
| InvestingCashFlow | -71.00K | -1.25M | -4.00M | 130.00K |
| CashFlowFromContinuingInvestingActivities | -71.00K | -1.25M | -4.00M | 130.00K |
| NetOtherInvestingChanges | 152.00K | |||
| NetInvestmentPurchaseAndSale | -52.00K | -1.25M | -4.00M | 0.00 |
| PurchaseOfInvestment | -52.00K | -1.25M | -4.00M | 0.00 |
| NetPPEPurchaseAndSale | -19.00K | 0.00 | 0.00 | -22.00K |
| PurchaseOfPPE | -19.00K | 0.00 | 0.00 | -22.00K |
| OperatingCashFlow | -1.53M | -15.70M | -19.61M | -21.76M |
| CashFlowFromContinuingOperatingActivities | -1.53M | -15.70M | -19.61M | -21.76M |
| TaxesRefundPaid | 8.78M | 0.00 | 490.00K | 1.42M |
| ChangeInWorkingCapital | -552.00K | -1.58M | -1.16M | -773.00K |
| ChangeInOtherCurrentLiabilities | 839.00K | -138.00K | 347.00K | -516.00K |
| ChangeInOtherCurrentAssets | 78.00K | 80.00K | 1.00M | 516.00K |
| ChangeInPayablesAndAccruedExpense | 0.00 | 0.00 | -1.35M | -685.00K |
| ChangeInPayable | -1.35M | -685.00K | ||
| ChangeInAccountPayable | 0.00 | 0.00 | -1.35M | -685.00K |
| ChangeInReceivables | -1.47M | -1.52M | -1.16M | -88.00K |
| OtherNonCashItems | 3.52M | -625.00K | 866.00K | |
| StockBasedCompensation | 1.43M | 1.73M | -1.41M | 5.17M |
| UnrealizedGainLossOnInvestmentSecurities | 1.76M | 402.00K | 869.00K | 0.00 |
| AssetImpairmentCharge | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 124.00K | 96.00K | 51.00K | 141.00K |
| DepreciationAndAmortization | 124.00K | 96.00K | 51.00K | 141.00K |
| Depreciation | 124.00K | 96.00K | 51.00K | 141.00K |
| OperatingGainsLosses | 159.00K | 1.52M | -3.05M | -1.93M |
| NetForeignCurrencyExchangeGainLoss | 158.00K | 1.52M | -3.18M | -1.90M |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | -28.00K | |
| NetIncomeFromContinuingOperations | -16.75M | -17.24M | -15.40M | -26.66M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for TLSA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|